RGEN Repligen Corp
Price (delayed)
$130.92
Market cap
$7.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.46
Enterprise value
$7.28B
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in
Highlights
RGEN's quick ratio is up by 32% year-on-year but it is down by 17% since the previous quarter
The debt has contracted by 3.6% YoY but it has grown by 2% from the previous quarter
RGEN's EPS has dropped by 172% year-on-year
The company's net income has shrunk by 172% YoY
Key stats
What are the main financial stats of RGEN
Market
Valuations
Earnings
Shares outstanding
56.15M
Market cap
$7.35B
Enterprise value
$7.28B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.72
Price to sales (P/S)
11.54
EV/EBIT
N/A
EV/EBITDA
90.71
EV/Sales
11.47
Revenue
$634.44M
Gross profit
$274.65M
Operating income
-$35.11M
Net income
-$25.51M
EBIT
-$6.3M
EBITDA
$80.26M
Free cash flow
$142.49M
Per share
Balance sheet
Liquidity
EPS
-$0.46
EPS diluted
-$0.46
Free cash flow per share
$2.55
Book value per share
$35.21
Revenue per share
$11.34
TBVPS
$25.04
Total assets
$2.83B
Total liabilities
$856.95M
Debt
$686.25M
Equity
$1.97B
Working capital
$939.25M
Debt to equity
0.35
Current ratio
8.41
Quick ratio
7.03
Net debt/EBITDA
-0.89
Margins
Efficiency
Dividend
EBITDA margin
12.7%
Gross margin
43.3%
Net margin
-4%
Operating margin
-5.5%
Return on assets
-0.9%
Return on equity
-1.3%
Return on invested capital
-0.5%
Return on capital employed
-0.2%
Return on sales
-1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGEN stock price
How has the Repligen stock price performed over time
Intraday
1.88%
1 week
-6.1%
1 month
-17.79%
1 year
-26.42%
YTD
-9.05%
QTD
2.89%
Financial performance
How have Repligen's revenue and profit performed over time
Revenue
$634.44M
Gross profit
$274.65M
Operating income
-$35.11M
Net income
-$25.51M
Gross margin
43.3%
Net margin
-4%
The operating income has plunged by 174% YoY
The operating margin has plunged by 173% YoY
The company's net income has shrunk by 172% YoY
The net margin has plunged by 171% YoY
Growth
What is Repligen's growth rate over time
Valuation
What is Repligen stock price valuation
P/E
N/A
P/B
3.72
P/S
11.54
EV/EBIT
N/A
EV/EBITDA
90.71
EV/Sales
11.47
RGEN's EPS has dropped by 172% year-on-year
The P/B is 36% less than the 5-year quarterly average of 5.7 and 13% less than the last 4 quarters average of 4.2
Repligen's equity has decreased by 2.2% QoQ
RGEN's P/S is 34% below its 5-year quarterly average of 17.1 and 15% below its last 4 quarters average of 13.4
Efficiency
How efficient is Repligen business performance
RGEN's ROA has dropped by 200% since the previous quarter and by 164% year-on-year
The return on equity has dropped by 172% year-on-year
The ROIC has plunged by 121% from the previous quarter and by 107% YoY
RGEN's return on sales has dropped by 121% since the previous quarter and by 111% year-on-year
Dividends
What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGEN.
Financial health
How did Repligen financials performed over time
RGEN's quick ratio is up by 32% year-on-year but it is down by 17% since the previous quarter
Repligen's current ratio has increased by 25% YoY but it has decreased by 19% QoQ
The debt is 65% less than the equity
Repligen's debt to equity has increased by 6% from the previous quarter but it has decreased by 2.8% YoY
The debt has contracted by 3.6% YoY but it has grown by 2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.